GlassScriptPhysician profile
Christopher James Taylor
NPI 1851747166
$1,709.13
in general payments reported to CMS, 2019-2025
29 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $478 · 2023: $120 · 2024: $100 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.32 | 2021-2024 | |
| Gilead Sciences, INC. | $158.37 | 2025 | Epclusa |
| Novo Nordisk INC | $130.17 | 2021-2025 | Wegovy |
| Pfizer INC. | $112.38 | 2021 | |
| Abbott Laboratories | $107.93 | 2021-2023 | Freestyle Libre 2 |
| Amgen INC. | $104.71 | 2021-2022 | |
| Lilly USA, LLC | $90.46 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $89.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.05 | 2021-2022 | |
| Exact Sciences Corporation | $60.05 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $59.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $58.46 | 2021-2022 | |
| Viiv Healthcare Company | $51.50 | 2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $43.71 | 2021 | |
| Organon LLC | $40.30 | 2023 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.74 | 2022 | |
| Dexcom, INC. | $28.95 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $24.40 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.34 | 2022 | |
| Edwards Lifesciences Corporation | $16.79 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $15.66 | 2021 | |
| Mylan Specialty L.P. | $15.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.56 | 2022 | |
| Merck Sharp & Dohme LLC | $14.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.48 | 2022 | |
| Radius Health, INC. | $12.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.16 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.